



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APR 19 2002

TECH CENTER 1600/2900

4/15/82

In re application of: Nelson, M. Bud Examiner: Saunders, David A.
Application No.: 09/643,277 Group Art: 1644
Filing Date: August 22, 2000 Docket No.: B-28 (old)
Title: COMPOSITIONS, ASSAY KITS, AND METHODS FOR USE
RELATED TO A DISEASE CONDITION COMPRISING MULTIPLE
SCLEROSIS AND/OR A PRO-MS IMMUNE RESPONSE

Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT AND SPECIES REQUIREMENT

Dear Sir:

In response to the Restriction Requirement dated December 6, 2001, Applicant provisionally elects, with traverse, the designated invention of Group II (Claims 10-17, 20-28, and 31-40) drawn to various methods of use.

In response to the Species Requirement of same date, Applicant provisionally elects, with traverse, the disclosed species of an epitope comprising a terminal alpha 2,6-linked sialic acid (“anti- α (2,6)NeuAc Ab”) and an anti-human IgG mAb.

The Restriction Requirement set a shortened statutory period for response of one month to expire January 6, 2002. Accordingly, Applicant submits herewith a petition and fee for a three-month extension of time under 37 CFR 1.136 (a) to extend the response time to April 6, 2002. Accordingly, this Response is timely filed.